4.7 Article

Association of Low-Density Lipoprotein Cholesterol-Related Genetic Variants With Aortic Valve Calcium and Incident Aortic Stenosis

Journal

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 312, Issue 17, Pages 1764-1771

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2014.13959

Keywords

-

Funding

  1. Swedish Cancer Society
  2. Swedish Medical Research Council
  3. Swedish Dairy Association
  4. Albert Pahlsson Foundation
  5. Gunnar Nilsson Foundation
  6. Malmo city council
  7. Swedish Heart-Lung Foundation
  8. Swedish National Health Service
  9. Crafoord Foundation
  10. Skane University Hospital
  11. Thorsten Westerstrom Foundation
  12. National Institute on Aging [N01-AG-12100]
  13. National Eye Institute
  14. National Institute on Deafness and Other Communication Disorders
  15. National Heart, Lung, and Blood Institute (NHLBI)
  16. National Institute on Aging Intramural Research Program
  17. Hjartavernd (the Icelandic Heart Association)
  18. Althingi (Icelandic parliament)
  19. NHLBI [N02-HL-64278, UL1 RR024156, R01-HL-071051, R01-HL-071205, R01-HL-071250, R01-HL-071251, R01-HL-071252, R01-HL-071258, R01-HL-071259, N01-HC-25195]
  20. American College of Cardiology Foundation/Merck Adult Cardiology Research Fellowship Award
  21. GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease Young Investigator Award
  22. Clinician-Scientist Salary Award from the Fonds de la Recherche du Quebec-Sante
  23. RI-MUHC/Merck Research Competition
  24. Canadian Institutes of Health Research [MOP-119380, MOP-126033]
  25. [N01-HC-95159]
  26. [N01-HC-95160]
  27. [N01-HC-95161]
  28. [N01-HC-95162]
  29. [N01-HC-95163]
  30. [N01-HC-95164]
  31. [N01-HC-95165]
  32. [N01-HC-95166]
  33. [N01-HC-95167]
  34. [N01-HC-95168]
  35. [N01-HC-95169]
  36. [N01-HC-65226]
  37. [R01 HL071739]
  38. Novo Nordisk Fonden [NNF14OC0011049] Funding Source: researchfish

Ask authors/readers for more resources

IMPORTANCE Plasma low-density lipoprotein cholesterol (LDL-C) has been associated with aortic stenosis in observational studies; however, randomized trials with cholesterol-lowering therapies in individuals with established valve disease have failed to demonstrate reduced disease progression. OBJECTIVE To evaluate whether genetic data are consistent with an association between LDL-C, high-density lipoprotein cholesterol (HDL-C), or triglycerides (TG) and aortic valve disease. DESIGN, SETTING, AND PARTICIPANTS Using a Mendelian randomization study design, we evaluated whether weighted genetic risk scores (GRSs), a measure of the genetic predisposition to elevations in plasma lipids, constructed using single-nucleotide polymorphisms identified in genome-wide association studies for plasma lipids, were associated with aortic valve disease. We included community-based cohorts participating in the CHARGE consortium (n = 6942), including the Framingham Heart Study (cohort inception to last follow-up: 1971-2013; n = 1295), Multi-Ethnic Study of Atherosclerosis (2000-2012; n = 2527), Age Gene/Environment Study-Reykjavik (2000-2012; n = 3120), and the Malmo Diet and Cancer Study (MDCS, 1991-2010; n = 28 461). MAIN OUTCOMES AND MEASURES Aortic valve calcium quantified by computed tomography in CHARGE and incident aortic stenosis in the MDCS. RESULTS The prevalence of aortic valve calcium across the 3 CHARGE cohorts was 32% (n = 2245). In the MDCS, over a median follow-up time of 16.1 years, aortic stenosis developed in 17 per 1000 participants (n = 473) and aortic valve replacement for aortic stenosis occurred in 7 per 1000 (n = 205). Plasma LDL-C, but not HDL-C or TG, was significantly associated with incident aortic stenosis (hazard ratio [HR] per mmol/L, 1.28; 95% CI, 1.04-1.57; P = .02; aortic stenosis incidence: 1.3% and 2.4% in lowest and highest LDL-C quartiles, respectively). The LDL-C GRS, but not HDL-C or TG GRS, was significantly associated with presence of aortic valve calcium in CHARGE (odds ratio [OR] per GRS increment, 1.38; 95% CI, 1.09-1.74; P = .007) and with incident aortic stenosis in MDCS (HR per GRS increment, 2.78; 95% CI, 1.22-6.37; P = .02; aortic stenosis incidence: 1.9% and 2.6% in lowest and highest GRS quartiles, respectively). In sensitivity analyses excluding variants weakly associated with HDL-C or TG, the LDL-C GRS remained associated with aortic valve calcium (P = .03) and aortic stenosis (P = .009). In instrumental variable analysis, LDL-C was associated with an increase in the risk of incident aortic stenosis (HR per mmol/L, 1.51; 95% CI, 1.07-2.14; P = .02). CONCLUSIONS AND RELEVANCE Genetic predisposition to elevated LDL-C was associated with presence of aortic valve calcium and incidence of aortic stenosis, providing evidence supportive of a causal association between LDL-C and aortic valve disease. Whether earlier intervention to reduce LDL-C could prevent aortic valve disease merits further investigation. Copyright 2014 American Medical Association. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available